BioSpace News Archive

Latest Study on “generic pharmaceuticals market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2023-2032”.

SiSaf Ltd, a biopharmaceutical company developing RNA therapeutics for rare diseases, today announced that an undisclosed licensee of its Bio-Courier delivery technology has completed target patient enrolment for the Phase II clinical trial of a treatment for mild-to-moderate (patchy) alopecia areata.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (“MustGrow”) wishes to provide additional information about the collaboration agreement (the “Agreement”) with Bayer AG (“Bayer”) which was announced December 11, 2023.

PharmaDrug Inc. is providing an update from the CEO to elaborate on the reasoning, vision and strategy for the previously announced and executed acquisition of Securedose Synthetics Inc. (“SecureDose”). (See press release dated November 7, 2023).

Value Eyecare Network, a pioneer in innovative eyewear solutions, is thrilled to announce the launch of Neurolux™, a groundbreaking product designed to bring comfort and relief to individuals suffering from migraines, photophobia (light sensitivity), and blepharospasm.

Rapid Medical™, a leading developer of advanced neurovascular devices, announced Japanese approval for its TIGERTRIEVER revascularization device.

Six years and 32 million cells later, scientists have created the first full cellular map of a mammalian brain.

MMS announced MAPS Public Benefit Corporation (MAPS PBC) submitted a New Drug Application (NDA) to the FDA for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified healthcare provider.

Orthopaedic disorders are lifechanging ailments that touch every one of us, whether personally, or through the challenging experiences of family members or friends.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has granted summary judgment to Acadia, confirming validity of the NUPLAZID® (pimavanserin) ‘740 composition of matter patent.